In This Section
MIRD Sponsored Continuing Education Courses
2010
- Radiation Risk/Toxicity Versus Benefits of Diagnostic and Therapeutic Nuclear Medicine Procedures: How to Best Put These in Perspective for Both Clinicians and Patients? Part I
- Radiation Risk/Toxicity Versus Benefits of Diagnostic and Therapeutic Nuclear Medicine Procedures: How to Best Put These in Perspective for Both Clinicians and Patients? Part II
2009
- ISRTRD/Alpha Symposium - Morning Session
- ISRTRD/Alpha Symposium – Afternoon Session
- ISRTRD/Alpha Refresher Course
- Pediatric Radiopharmaceutical Dosimetry Symposium – Part I
- Pediatric Radiopharmaceutical Dosimetry Symposium - Part II
- ISRTRD Refresher Course Thyroid Dosimetry/Radiobiology & Imaging Quantitation
- ISRTRD Refresher Course - Computational Phantoms for Imaging & Dosimetry
- ISRTRD Refresher Course - Patient-Specific Dosimetry
- Patient-Specific Dosimetry for Systemic Radiotherapy: Opportunities for Personalizing Cancer Therapy
2008
- MIRD I: Accuracy and Precision in Internal Dose Assessments: Quantitative Imaging
- MIRD II: Accuracy and Precision in Internal Dose Assessments: Dosimetry and Response
2007
- Internal Dosimetry Methods in Nuclear Medicine - Part I
- Internal Dosimetry Methods in Nuclear Medicine - Part II
2006
- Bystander and Low-Dose Rate Effects - Are These Relevant to Radionuclide Therapy: Part I
- Bystander and Low-Dose Rate Effects - Are These Relevant to Radionuclide Therapy: Part II
2005
- Advances in Patient-Specific Dosimetry: Part 1 – Voxel-Based Anatomic models.
- Advances in Patient-Specific Dosimetry: Part 2 – Tools for Patient Dose Assessment.
- Joint sponsorship with the REIR Committee: Radiation Risk Coefficients – Our Current State of Knowledge of Patient Risk.
2004
- Part 1: Optimization of Radiation Dosimetry for Radionuclide Therapy after FDA Approval.
- Part 2: Radiation Dosimetry Methods for Radionuclide Therapy in Clinical Trials: What is Practical?
2003
- Kidney Dose Response to Radionuclide Therapy (Sessions I and II). Presentations published in: Cancer Biotherapy & Radiopharmaceuticals 19: 2004. Editors: Robert K. Oldham and Gerald L. Denardo.
- G Sgouros. Introduction to Kidney Dose-Response for Radionuclide Therapy (.PDF file).
- H Breitz. Clinical Aspects of Radiation Nephropathy (.PDF file).
- R Dale. Use of the Linear-Quadratic Radiological Model for Quantifying Kidney Response in Targeted Radiotherapy (.PDF file).
- A Green, A Flynn, RB Pedley, et.al. Ninuniform Absorbed Dose Distribution in the Kidney: The Influence of Organ Architecture (.PDF file).
- J O’Donoghue. Relevance of External Beam Dose-Response Relationships to Kidney Toxicity Associated with Radionuclide Therapy (.PDF file).
- B Wessels. Summary and Perspectives on Kidney Dose-Response to Radionuclide Therapy (.PDF file).
Acknowledgement: Courtesy of Mary Ann Liebert, Inc., Publishers, www.liebertpub.com/cbr
2002
- Patient-Specific Radionuclide Dosimetry & Scientific Contributions of the Radiation Physics Group at Lund University, Sweden.
2001
- Introduction to Radionuclide Therapy: The Role and Options for Dosimetry in Clinical Practice. Presentations published in: Cancer Biotherapy & Radiopharmaceuticals 17: 2002. Editors: Robert K. Oldham and Gerald L. Denardo.
- JA Siegel. Guest Editor's Introduction (.PDF file).
- SR Thomas. Options for Radionuclide Therapy: From Fixed Activity to Patient-Specific Treatment Planning (.PDF file).
- R Meredith. Clinical Trial Design and Scoring of Radionuclide Therapy Endpoints: Normal Organ Toxicity and Tumor Response (.PDF file).
- JC Sisson. Practical Dosimetry of I-131 in Patients with Thyroid Carcinoma (.PDF file).
- GL DeNardo, CL Hartmann Siantar, SJ DeNardo. Radiation Dosimetry for Radionuclide Therapy in a Nonmyeloablative Strategy (.PDF file).
- H Breitz. Dosimetry in a Myeloablative Setting (.PDF file).
Acknowledgement: Courtesy of Mary Ann Liebert, Inc., Publishers, www.liebertpub.com/cbr